10x Genomics (TXG)
(Real Time Quote from BATS)
$21.46 USD
+1.81 (9.21%)
Updated Aug 13, 2024 03:51 PM ET
3-Hold of 5 3
D Value A Growth D Momentum B VGM
Price, Consensus and EPS Surprise
TXG 21.46 +1.81(9.21%)
Will TXG be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TXG based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TXG
10x Genomics (TXG) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
10x Genomics (TXG) Reports Q2 Loss, Tops Revenue Estimates
TXG: What are Zacks experts saying now?
Zacks Private Portfolio Services
Unlocking Q2 Potential of 10x Genomics (TXG): Exploring Wall Street Estimates for Key Metrics
Azenta (AZTA) Q3 Earnings and Revenues Top Estimates
IRhythm Technologies (IRTC) Reports Q2 Loss, Tops Revenue Estimates
Other News for TXG
Starbucks To Rally Around 43%? Here Are 10 Top Analyst Forecasts For Tuesday
10x Genomics price target lowered by $4 at Morgan Stanley, here's why
Navigating 11 Analyst Ratings For 10x Genomics
What's Driving Doximity Inc's Surprising 50% Stock Rally?
Catherine Wood's Strategic Acquisition in 10x Genomics Inc.